| Title |
Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis
|
|---|---|
| Published in |
Biologics: Targets & Therapy, November 2013
|
| DOI | 10.2147/btt.s34935 |
| Pubmed ID | |
| Authors |
Tarun Kaushik, Muhammad Magdi Yaqoob |
| Abstract |
Peginesatide is the newest erythropoietin-stimulating agent (ESA) in the quest for the ideal treatment of anemia in chronic kidney disease (CKD) patients. Reduced frequency of administration along with a possibly lower cost as a result of simpler manufacturing techniques compared with other available agents makes peginesatide a highly desirable product in the competitive ESA market. Peginesatide is noninferior to the other ESAs, and has a good safety profile in patients on hemodialysis. The higher rates of adverse cardiovascular events reported in CKD patients not on dialysis in the recent Phase III studies require further, better planned, studies. Peginesatide had to be withdrawn from the market in the US after some reports of hypersensitivity reactions to the drug. This is a setback, but the scientific advances gained as a result of this product development can be used to develop other, newer products. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 24 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 21% |
| Student > Bachelor | 4 | 17% |
| Student > Ph. D. Student | 4 | 17% |
| Other | 3 | 13% |
| Student > Master | 2 | 8% |
| Other | 3 | 13% |
| Unknown | 3 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 33% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 13% |
| Chemistry | 3 | 13% |
| Nursing and Health Professions | 2 | 8% |
| Biochemistry, Genetics and Molecular Biology | 2 | 8% |
| Other | 3 | 13% |
| Unknown | 3 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 November 2013.
All research outputs
#22,759,802
of 25,374,917 outputs
Outputs from Biologics: Targets & Therapy
#245
of 284 outputs
Outputs of similar age
#200,358
of 226,637 outputs
Outputs of similar age from Biologics: Targets & Therapy
#5
of 8 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 284 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,637 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.